Author:
Alexander James L,Liu Zhigang,Muñoz Sandoval Diana,Reynolds Catherine,Ibraheim Hajir,Anandabaskaran Sulak,Saifuddin Aamir,Castro Seoane Rocio,Anand Nikhil,Nice Rachel,Bewshea Claire,D'Mello Andrea,Constable Laura,Jones Gareth R,Balarajah Sharmili,Fiorentino Francesca,Sebastian Shaji,Irving Peter M,Hicks Lucy C,Williams Horace R T,Kent Alexandra J,Linger Rachel,Parkes Miles,Kok Klaartje,Patel Kamal V,Teare Julian P,Altmann Daniel M,Goodhand James R,Hart Ailsa L,Lees Charlie W,Boyton Rosemary J,Kennedy Nicholas A,Ahmad Tariq,Powell Nick,Chukwurah Ijeoma,Haq Sulaimaan,Shah Parita,Wilken-Smith Stephanie,Ramanathan Anitha,Patel Mikin,Romanczuk Lidia,King Rebecca,Domingo Jason,Shamtally Djamila,Mendoza Vivien,Sanchez Joanne,Stark Hannah,Knight Bridget,Bee Louise,Estember Charmaine,Barnes Anna,Watkins Darcy,Stone Sam,Kirkwood John,Parkinson Marian,Gardner-Thorpe Helen,Covil Kate,Derikx Lauranne,Gros Alcalde Beatriz,Lee Irish,Cipriano Bessie,Ruocco Giuseppe,Baden Manisha,Cooke Graham,Pollock Katrina,Kourampa Evgenia,Pasquale Ciro,Robisco-Diaz Elena,Bhatti Suhaylah
Subject
Gastroenterology,Hepatology
Reference32 articles.
1. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: test negative design study;Chung;BMJ,2021
2. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data;Haas;Lancet,2021
3. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape;Tregoning;Nat Rev Immunol,2021
4. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study;Alexander;Lancet Gastroenterol Hepatol,2022
5. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab;Lin;Nat Commun,2022